as 06-26-2025 4:00pm EST
Stocks
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | LA PALMA |
| Market Cap: | 623.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 611.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.40 - $33.66 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
LIMN Breaking Stock News: Dive into LIMN Ticker-Specific Updates for Smart Investing
The information presented on this page, "LIMN LIMINATUS PHARMA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.